MapLight Therapeutics获得1.5亿美元PIPE资金

2026-08-13 21:49

MapLight Therapeutics (MPLT) has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing for gross proceeds of ~$150M.
In the PIPE, MapLight is selling an aggregate of 9.20M shares of its common stock at a price of $11.38 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3.98M shares of common stock at a purchase price of $11.38 per pre-funded warrant.
Each pre-funded warrant has an exercise price of $0.0001 per share of common stock, will be immediately exercisable, subject to certain conditions set forth in each pre-funded warrant, and will not expire. The PIPE is expected to close on August 14, 2026.
MapLight intends to use the proceeds from the PIPE primarily to support the continued advancement of ML-007C-MA, including funding the ongoing VISTA Phase 2 study in Alzheimer’s disease psychosis as well as the ZEPHYR-2 registrational Phase 3 study in schizophrenia and its associated open-label safety study, and for working capital and other general corporate purposes.
Source: Press Release

More on MapLight Therapeutics, Inc.